Biovian, a contract development and manufacturing organization (CDMO), announced on Feb. 1, 2024 that it was combining with CDMO 3P Biopharmaceuticals to form 3PBIOVIAN under the two companies’ common shareholder, Keensight Capital. The new group, 3PBIOVIAN, will offer end-to-end development and manufacturing services for protein expression systems and viral vectors for both drug substances and drug products from preclinical to commercial phases.
3PBIOVIAN will be a global CDMOoffering microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. It will also provide fill/finish services for recombinant proteins and viral vectors. The group has manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland.